Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus.

Syvänne, Mikko; Vuorinen-Markkola, Helena; Hilden, H.; Taskinen, Marja‐Riitta

doi:10.1161/01.atv.13.2.286

Cited by 64 publications

(26 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The improvement in clearance in the healthy women would be expected to reduce the atherosclerotic risk in healthy premenopausal women, which is a benefit not seen in our diabetic patients. However, both lifestyle (28,29) and pharmacological (30,31) intervention may improve chylomicron clearance, so women with diabetes may particularly benefit from such measures.…”

Section: Results -Subject Characteristics Are Shown Inmentioning

confidence: 99%

Premenopausal Advantages in Postprandial Lipid Metabolism Are Lost in Women With Type 2 Diabetes

et al. 2003

View full text Add to dashboard Cite

OBJECTIVE -Women with type 2 diabetes appear to lose the protection against cardiovascular disease afforded by estrogens. We examined the effects of menopausal status on postprandial clearance of dietary fat in healthy and diabetic women.RESEARCH DESIGN AND METHODS -Fasting subjects (premenopausal and postmenopausal control subjects, premenopausal and postmenopausal diabetic women, all n ϭ 8) were given a meal containing the stable isotope 1,1,1-13 C-tripalmitin, with blood and breath sampled for 6 and 24 h, respectively, in the postprandial period. Lower levels of 13 C-palmitic acid ( 13 C-PA) in the triglyceride fraction implies more efficient chylomicron clearance, lower levels of 13 C-PA in the nonesterified fatty acid (NEFA) fraction implies improved dietary NEFA entrapment, and higher levels of 13 CO 2 in the breath denote more efficient of oxidation of dietary-derived lipid.RESULTS -In diabetic women, there were no differences between the pre-and postmenopausal groups for any of these parameters. In contrast, premenopausal control subjects, compared with postmenopausal control subjects, had lower CONCLUSIONS -The premenopausal advantage in clearance of dietary lipid is not seen in premenopausal diabetic women. This is likely to promote an atherogenic lipoprotein profile and may contribute to the loss of cardiovascular disease protection seen in diabetic women. Diabetes Care 26:3243-3249, 2003P atients with type 2 diabetes have an increased cardiovascular risk, which is particularly marked in diabetic women (1). In the nondiabetic population, women are relatively protected against coronary heart disease (CHD) when compared with men, an effect attributed to the physiological effects of estrogens (2,3). In contrast, diabetic women have an equivalent rate of CHD to diabetic men, appearing to lose the protection of estrogens (1).There are many contender mechanisms to account for the high CHD risk observed in diabetes (4), including diabetic dyslipidemia, which is thought to be particularly atherogenic and is characterized by fasting hypertriglyceridemia, low HDL cholesterol, and small dense LDL (4). The impact of the postprandial triglyceride load will be underestimated by examining fasting triglyceride values, as the typical western diet and pattern of feeding usually results in maintenance of the postprandial state for ϳ16 h each day (5). Postprandial triglyceride levels are determined by the metabolism of chylomicrons and VLDL. Chylomicrontriglyceride is hydrolyzed by the action of the enzyme lipoprotein lipase (LPL) releasing nonesterified fatty acids (NEFAs), the remaining chylomicron remnants being taken up by the liver via LDL receptors (6). Premenopausal nondiabetic women have been shown to have lower postprandial triglyceride levels than postmenopausal women (7,8), probably due to upregulation of hepatic LDL receptor by estrogens (9), thus increasing chylomicron remnant clearance. However, reduced chylomicron clearance is a feature of diabetes (10).We hypothesized that impaired clearance of circulatin...

show abstract

Section: Results -Subject Characteristics Are Shown Inmentioning

confidence: 99%

Premenopausal Advantages in Postprandial Lipid Metabolism Are Lost in Women With Type 2 Diabetes

et al. 2003

View full text Add to dashboard Cite

show abstract

“…Serum total cholesterol and TG were determined with automated enzymatic methods. 29 Serum apoB was measured by an immunochemical assay (Orion Diagnostica). Lipoprotein fractions, LDL, HDL, and serum apo concentrations were determined by an immunoturbidimetric method with a commercially available kit (Boehringer Mannheim) based on sequential flotation as described.…”

Section: Analytical Proceduresmentioning

confidence: 99%

Coronary Flow Reserve in Young Men With Familial Combined Hyperlipidemia

et al. 1999

View full text Add to dashboard Cite

show abstract

“…Serum total cholesterol and triglycerides were determined with automated enzymatic methods. 23 HDL cholesterol was determined as described. 24 Familial hypercholesterolemia was excluded from each pedigree by determining the LDL receptor status of the proband by using the lymphocyte culture method.…”

Section: Biochemical Analysesmentioning

confidence: 99%

Haplotypes of the ApoA-I/C-III/A-IV Gene Cluster and Familial Combined Hyperlipidemia

Tahvanainen

Pajukanta

Porkka

et al. 1998

ATVB

View full text Add to dashboard Cite

Abstract-Familial combined hyperlipidemia (FCHL) is the most frequent familial lipoprotein disorder associated with premature coronary heart disease. However, no genetic defect(s) underlying FCHL has been identified. A linkage between FCHL and the apoA-I/C-III/A-IV gene cluster has been reported but not verified in other populations. A recent study identified FCHL susceptibility haplotypes at this gene cluster. To study whether such haplotypes are also associated with FCHL susceptibility in Finns, we studied 600 well-defined Finnish FCHL patients and their relatives belonging to 28 extended FCHL families by using haplotype, linkage, sib-pair, and linkage disequilibrium analyses. Key Words: apoA-I Ⅲ apoC-III Ⅲ apoA-IV Ⅲ familial combined hyperlipidemia Ⅲ coronary heart disease F amilial combined hyperlipidemia (FCHL), originally described by 3 independent groups, 1-3 is characterized by an elevation of cholesterol and/or triglyceride levels. In Western societies, the condition is found in 1% to 2% of the population and in Ϸ10% of survivors of myocardial infarction, designating FCHL as one of the most frequent familial dyslipidemias associated with premature coronary heart disease (CHD). In affected subjects, a common characteristic is an increase in small, dense LDL particles.4-6 A consistent metabolic finding in FCHL is an increased apoB plasma level, 7,8 which is due to either increased production or lowered clearance of apoB-containing lipoproteins. 9 -11 Association between the apoA-I/C-III/A-IV gene cluster on chromosome 11 and FCHL has been the subject of several studies. An association between FCHL and an XmnI restriction fragment polymorphism in the 5Ј-flanking region of the apoA-I gene was reported, 12 and the finding was later confirmed by linkage (logarithm of the odds [lod] score, 6.86) without recombinants in 7 families. 13 Further evidence for an association between this gene cluster and FCHL has been provided by other groups, 14 -16 but the findings have also been challenged, [17][18][19][20] and the positive linkage result has not been confirmed. An explanation for this controversy may be provided by a recent study, 21 in which the contribution of the apoA-I/C-III/A-IV gene cluster is presented as an epistatic interaction between different haplotypes, a finding that may also partially explain the paradigm of the complex and varying phenotypes of FCHL. A specific combination of haplotypes (1-1-2/2-2-1, "the high-risk haplotype combination") derived from polymorphic XmnI and MspI sites in the 5Ј-flanking region of the apoA-I gene and the SstI site in the 3Ј-untranslated region of the apoC-III gene was reported to be more frequent in hyperlipidemic patients (frequency, 0.06) than in normolipidemic relatives (frequency, 0.03, PϽ0.05) or spouses (frequency, 0.005, Pϭ0.01). The aim of the current study was to test whether these specific haplotypes are also associated with FCHL in Finnish FCHL families. Methods Study SubjectsThe collection of carefully documented pedigrees with several affected indivi...

show abstract

Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus.

Cited by 64 publications

References 59 publications

Premenopausal Advantages in Postprandial Lipid Metabolism Are Lost in Women With Type 2 Diabetes

Premenopausal Advantages in Postprandial Lipid Metabolism Are Lost in Women With Type 2 Diabetes

Coronary Flow Reserve in Young Men With Familial Combined Hyperlipidemia

Haplotypes of the ApoA-I/C-III/A-IV Gene Cluster and Familial Combined Hyperlipidemia

Contact Info

Product

Resources

About